Full-Time

Principal/Senior Principal

Financial Investors Consulting

Posted on 9/8/2025

IQVIA

IQVIA

10,001+ employees

Analytics, technology, and clinical research services.

No salary listed

London, UK

In Person

Category
Consulting (1)
Required Skills
Management
Requirements
  • Private Equity Client Relationship Management and Delivery - Principal owner of client engagements with financial investors in healthcare/life sciences (e.g. Private Equity, VCs, Hedge Funds), focused on client satisfaction and outstanding client deliverables. Extensive network within the Private Equity and VC community. Proven capability to identify new revenue opportunities with existing clients.
  • Team Development/Management - Proven skills in identifying, recruiting, mentoring/coaching, and retaining top talent for CONSULTING SERVICES practice teams.
  • Business Development - Proven success selling complex strategy and operations engagements to the top Private Equity and VC firms. Actively participate in proposal development and ongoing pre-sales meetings with potential new client organizations. Deep experience in selling life sciences due diligence, valuation and strategy work.
  • Pharmaceutical and Life Sciences Strategy Experience - Ability to speak in detail with Boards, CEOs, COOs, and CFOs about commercial strategy services/solutions, commercial and technical due diligence and transaction advisory, specifically in the life sciences industry segment, in a meaningful manner with depth of content knowledge.
  • Senior Level Solution Selling - Proven ability to build relationships, identify client pain points, and develop custom solutions at the CEO/COO/CFO level (ideally providing comprehensive and authoritative knowledge in strategy, due diligence and transaction advisory solutions demonstrated through speaking, writing, and general eminence.
  • International Experience and US Private Equity/VC Network - Has the experience to craft client strategies that are specific with regard to international geography.
  • Communications/Executive Presence - Expresses ideas in a clear and concise manner; tailors message to target audience with the gravitas to build relationships to sell services and recruit practitioners.
  • Industry and Investment Trends - Maintains a constant focus on industry, client and competitive trends in the life sciences industry. Applies this knowledge to both active client engagements and business/client development activities. Has a good grasp of recent trends in M&A, divestments, carve outs and other life-sciences transactions.
  • Working knowledge of Financial Statements & Corporate Finance - Has a good understanding of P&L, Balance Sheet and Cash Flow management. Ability to engage with senior stakeholders in a firm (Boards, CEOs, CFOs) to discuss financial value creation opportunities.
  • Analytical Problem-Solving - Applies an analytical approach to solving problems and reaching logical conclusions. Gathers information from a variety of sources and quickly gains an understanding of it. Works effectively with complicated, conflicting or ambiguous information, and looks beyond the surface of issues to identify their underlying patterns and causes.
  • Clear Oral Communication - Ability to speak clearly and fluently. Demonstrates a logical, structured approach, adapts to the needs of the situation and the nature of the audience; confirms the audience has understood the message. Beyond presenting clearly, this competency is also concerned with ensuring strong two-way communication.
  • Clear Written Communication - Ability to write clearly and succinctly. Adapts style and content; meets demands of the situation and audience. Communicates clearly and effectively uses well-structured, logical arguments and avoids unnecessary technical or complex language.
  • Commercial Awareness - Considers flow of money and resources through an organization, and the need to get maximum value at each stage. Seeks to achieve commercial objectives, such as profitability, so the business can be as competitive and successful as possible.
  • Cooperative Teamwork - Builds supportive relationships within a team, based on trust and respect. Requires listening to others, adapts to other people's different work styles and focuses on shared goals. Willing to challenge others and accepts challenges as a way of getting the best results for the team.
  • Coping with Pressure - A positive attitude in stressful situations or following failures. Ability to manage one’s own emotions, willing to take on challenging tasks, and energy to remain focused on those tasks when presented with obstacles.
  • Customer Focus - Develops strong, lasting relationships with clients. Possesses desire to understand and satisfy customers’ needs and exceed expectations whenever possible. Concern with clients inside or outside the organization; internal customers may be other departments or individuals from the same organization.
  • Decision-Making - Makes clear, appropriate decisions. Performs with incomplete or ambiguous information, and while under time pressure. Resilience in making unpopular decisions when necessary, and taking responsibility for outcomes and impacts of those decisions.
  • Flexibility - Responds well to change. Positive attitude toward change and a readiness to adapt when presented with new information, new situations or shifting priorities.
  • Influencing - Balances the need to shape outcomes in short term while maintaining successful long-term relationships. Knows how to motivate and inspire to achieve a common goal, and demonstrates key strategic negotiation tactics. Uses personal and professional contacts to influence people across teams or organizations.
  • Initiative - Constantly looks for things to do. Self-confident and proactive; generates activity for themselves rather than waiting for instruction. Prepared to take risks if potential benefit in results.
  • Innovation - Turns creative ideas into original solutions. Produces new or different approaches in current situations and enables creativity in others. Involved in generating ideas and seeing them through to implementation.
  • Management of Others - Enables others to perform. Sets a clear direction and delegates fairly and appropriately allowing direct reports the means to achieve their goals. Looks for opportunities to develop individuals by encouraging them to take on greater responsibility and make decisions for themselves.
  • Planning and Organizing - Establishes and prioritizes tasks and objectives in order to manage time and resources appropriately. Sets deadlines based on the time required, and on how each part of the plan affects others. Prepares backup plans in case the situation changes.
  • Strategic Vision - Creates a clear view of the future of the business. Considers the long-term goals of the organization and defines the strategy to achieve this. Takes into account the current environment in which the business operates and anticipates future changes or challenges for the organization.
  • Technological Orientation - Shows comfort and aptitude using technology in order to reach goals more efficiently, and to a higher standard of quality. Welcomes advancements in technology and is willing to understand and implement them. Uses technology appropriately and helps others to appreciate and understand the benefits of using technology.
Responsibilities
  • Develop and deliver insightful, value-added strategies that address complex client issues.
  • Create and elevate new business opportunities through the identification of value-added follow-on work and identify new revenue opportunities with existing and new client organisations.
  • Act as principal owner of client engagements; ultimate responsibility for client satisfaction and delivering high levels of quality/added value.
  • Provide follow-up with clients after project deliverables have been completed to ensure client satisfaction.
  • Allocate direction, advice, and intellectual leadership to clients and delivery teams.
  • Provide high level input and ensure development of client reports and presentations.
  • Ability to deliver all or significant portions of findings to clients.
  • Lead thought leadership and firm building initiatives.
  • Remain current on industry, clients, and competitive trends and directions in order to anticipate and identify new business challenges and issues with assigned clients.
  • Contribute to the enhanced awareness of Consulting Services in the marketplace, e.g. through speaking engagements, client meetings, and publications.
  • Participate in annual performance review team processes.
  • Engage in recruitment and selection of new staff.
  • Mentor, coach, and share subject matter expertise with others to help develop individuals and capabilities delivering world-class solutions for clients.

IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenues hit $4.15B with $34.2B R&D backlog driving growth.
  • Charles River acquisition adds $144M revenue preclinical AI for oncology.
  • 19 of top 20 pharmas adopt IQVIA.ai agents boosting commercialization.

What critics are saying

  • Parexel and ICON capture biotech clients with lower-cost trials in Asia.
  • EU AI Act fines IQVIA.ai 6% of revenues starting August 2026.
  • Pharma in-house AI internalizes analytics slashing 40% Technology revenues.

What makes IQVIA unique

  • IQVIA Connected Intelligence combines 1.2 billion patient records with AI for life sciences.
  • 2016 Quintiles-IMS merger uniquely integrates CRO services and healthcare analytics.
  • IQVIA.ai with NVIDIA deploys 192 agents across 64 use cases for pharma workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 10th, 2026
IQVIA gains 22.6% on AI platform launch, strategic acquisitions and sustainability progress

IQVIA Holdings has gained 22.6% over the past year, outperforming its industry's 5.8% growth. The company expects long-term earnings per share growth of 13%, with year-over-year growth of 11.6% in 2026 and 16.1% in 2027. IQVIA recently launched IQVIA.ai in collaboration with NVIDIA, integrating AI technologies into life sciences workflows. The platform combines analytics, automation and decision-making to improve efficiency and accelerate research, with strong early adoption from leading pharmaceutical companies. The company is expanding through strategic acquisitions, including drug discovery assets from Charles River Laboratories, adding in vitro services and AI-driven platforms. A partnership with Duke Clinical Research Institute aims to accelerate clinical research in obesity-related conditions, enhancing IQVIA's end-to-end offerings across the drug development lifecycle.

Yahoo Finance
Apr 5th, 2026
IQVIA launches unified agentic AI platform with Nvidia for life sciences

IQVIA Holdings has launched IQVIA.ai, a unified agentic AI platform developed in collaboration with Nvidia, specifically designed for the life sciences industry. The platform integrates IQVIA's healthcare-grade AI and data assets with Nvidia's technology stack, including Nemotron and the NeMo Agent Toolkit, to enhance operational efficiency across clinical, commercial and real-world domains. At launch, 19 of the top 20 pharmaceutical companies had already begun incorporating IQVIA's agents into their processes. The platform functions as a digital command centre, embedding intelligent agents directly into existing workflows whilst maintaining strict healthcare regulatory and privacy standards. IQVIA.ai features a catalogue of ready-to-use and configurable intelligent agents tailored for life sciences workflows. Additional agents and features are scheduled for release in Q4 2026.

IQVIA Holdings, Inc.
Mar 16th, 2026
IQVIA unveils IQVIA.ai, a unified agentic AI platform powered by NVIDIA to improve efficiency and decision making across Life Sciences.

IQVIA unveils IQVIA.ai, a unified agentic AI platform powered by NVIDIA to improve efficiency and decision making across Life Sciences. 03/16/2026 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- IQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced at NVIDIA GTC the launch of IQVIA.ai, a unified agentic AI platform purpose-built to help life sciences organizations transform how they operate, make decisions and innovate across clinical, commercial and real-world domains. Combining IQVIA's deep life sciences expertise, Healthcare-grade AI(R) and data assets with NVIDIA Nemotron, NeMo Agent Toolkit, Dynamo and LangChain, IQVIA.ai is designed to continuously learn from complex operational feedback, while operating securely and in alignment with healthcare regulatory, privacy and quality standards - enabling responsible AI adoption at scale. IQVIA began its collaboration with NVIDIA more than a year ago to develop the agentic AI foundation that underpins IQVIA.ai. As part of this ongoing commitment to AI innovation, IQVIA has filed more than 100 AI-related patents and deployed more than 150 intelligent agents across internal teams and client environments. To date, 19 of the top 20 pharmaceutical companies have begun incorporating IQVIA agents into their workflows, underscoring broad industry trust in IQVIA's AI capabilities. Built on decades of IQVIA leadership at the intersection of data, technology and life sciences, IQVIA.ai represents a significant advancement in how AI is applied at enterprise scale. Unlike many standalone AI tools or horizontal AI platforms, IQVIA.ai enables organizations to embed intelligence directly into workflows, streamline complex operations and unlock greater value from data - while operating at the trust, quality and compliance levels demanded by regulated life sciences environments. IQVIA.ai serves as a digital command center that brings together AI-driven automation, advanced analytics and decision support within a single, unified experience. By orchestrating tasks and insights across multiple data sources and functions, the platform helps organizations accelerate research and analysis, improve operational efficiency and support more confident, timely decision making. IQVIA.ai combines conversational AI with an extensible catalog of intelligent agents, both ready-to-use and configurable, designed around real-world life sciences workflows. Through this single platform, customers can securely access, deploy and scale IQVIA powered AI tools, agents, insights and workflows, unifying intelligence and execution under one IQVIA-led architecture. "IQVIA.ai reflects our longstanding commitment to translating innovation into practical, high impact solutions for life sciences," said Bernd Haas, senior vice president, AI and Technology Solutions at IQVIA. "By bringing together our data, expertise and Healthcare-grade AI within a unified, agentic platform, IQVIA.ai enables organizations to move faster and smarter while meeting the rigorous standards of trust and reliability that are required in the industry." "The sheer volume and complexity of data within the life sciences industry have outpaced traditional methods of research and manual workflow," said Kimberly Powell, vice president of Healthcare and Life Sciences at NVIDIA. "By combining IQVIA's proprietary data and deep domain expertise with NVIDIA technology, IQVIA.ai provides the advanced agentic infrastructure needed to transform this data into actionable insights, enabling organizations to scale AI responsibly and accelerate the delivery of life-changing treatments." The initial release of IQVIA.ai will focus on high-value use cases across clinical, commercial and real-world, with additional agents and capabilities expected in Q4. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high quality health data, Healthcare grade AI(R), advanced analytics, the latest technologies, and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology, and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Forward-Looking Statements This press release contains forward-looking statements based on current expectations, including statements regarding the expected capabilities, benefits and timing of IQVIA.ai and related offerings. These statements involve risks and uncertainties that could cause actual results to differ materially. Additional information about factors that could affect future results is contained in IQVIA's most recent filings with the Securities and Exchange Commission. IQVIA undertakes no obligation to update any forward-looking statements. Kerri Joseph, IQVIA Investor Relations [email protected] +1.973.541.3558 Multimedia Files:

Yahoo Finance
Mar 10th, 2026
IQVIA stock slides 28% from 52-week high as margin compression weighs on healthcare research giant

IQVIA Holdings, a Durham, North Carolina-based healthcare research company, has significantly underperformed the Nasdaq, falling 20.8% year-to-date and 6.8% over the past year, compared to the Nasdaq's 2.4% YTD decline and 24.7% annual gain. The $30.3 billion company, which provides analytics and clinical research services to the life sciences industry, has dropped 27.7% from its 52-week high of $247.05 reached on 9 January. Shares declined 10.7% on 5 February following fourth-quarter results, despite beating Wall Street expectations with adjusted earnings per share of $3.42 and revenue of $4.4 billion. The underperformance stems from margin compression and concerns about sustainability, as operating margins declined due to pass-through revenue growth and product mix changes.

PHARMPROM
Mar 5th, 2026
IQVIA Enters the Early-Stage Drug Development Market by Acquiring Charles River Laboratories Assets

IQVIA enters the early-stage drug development market by acquiring Charles River Laboratories assets. 06.03.2026 Contract research organization Charles River Laboratories has signed agreements to sell several of its divisions. The European early-stage drug development assets (Discovery Services) will be transferred to IQVIA, while the contract manufacturing (CDMO) business will be acquired by the investment firm GI Partners. Strategic motives: why IQVIA needs preclinical assets. The transaction reflects the transformation of IQVIA's business model. The company, historically specializing in healthcare data analytics and clinical trials (late phases), is expanding its presence in the earliest stages of drug creation. The perimeter of the deal includes five European research sites, an artificial intelligence platform for small molecule discovery, and New Approach Methodologies (NAMs) for animal-free testing. These assets have direct synergy with IQVIA's core analytical business: * Charles River's AI platform complements IQVIA's big data competencies, allowing the direct application of machine learning algorithms to model new molecules. * The acquisition allows IQVIA to offer pharmaceutical clients a continuous cycle of services: from molecule discovery and in vitro testing to clinical trials and drug commercialization. Financial parameters and transaction terms. The base value of the deal between Charles River and IQVIA is $145 million in cash, with the possibility of additional contingent payments of up to $10 million. The revenue of the acquired assets for 2025 was $144 million. Target therapeutic areas include oncology, neuroscience, immunology, and orphan diseases. The second agreement involves the sale of the CDMO and Cell Solutions divisions (manufacturing facilities in the US and the UK) to the investment company GI Partners. The structure of this transaction provides for contingent performance-based payments tied to the future financial results of the assets. The total revenue of these divisions in 2025 was $143 million. Implications for Charles River Laboratories. The divestiture of these divisions is part of Charles River's portfolio optimization. The sale of non-core assets will lead to a decrease in the company's reported revenue in 2026 by more than $200 million. At the same time, the restructuring will ensure an increase in the non-GAAP operating margin by at least 100 basis points, which allowed the company to raise its annual adjusted profit forecast. Both transactions are expected to close in the second quarter of 2026. Summary parameters of Charles River Laboratories M&A transactions. | Parameter | Value | | Seller | Charles River Laboratories | | Buyers | IQVIA Holdings Inc. and GI Partners | | Transaction rationale for IQVIA | Integration of early development (AI, in vitro) with clinical expertise | | IQVIA transaction value | $145 million in cash (+ up to $10 million in contingent payments) | | Assets for IQVIA | 5 research sites in Europe (2025 revenue: $144 million) | | GI Partners transaction terms | Contingent payments dependent on financial results | | Assets for GI Partners | CDMO and Cell Solutions divisions (2025 revenue: $143 million) | | Target closing date | Q2 2026 |

INACTIVE